Form 4: Orthofix Medical Director Alan Lee Bazaar Receives Significant Equity Award

Orthofix Medical Inc. Director Alan Lee Bazaar was granted 18,841 deferred stock units, vesting on June 18, 2025, increasing his total beneficial ownership to 49,824 shares.

Summary

• Alan Lee Bazaar, a Director of Orthofix Medical Inc. (OFIX), acquired 18,841 shares of common stock in the form of deferred stock units (DSUs).
• The transaction date, which is the vesting date for these DSUs, is June 18, 2025.
• These DSUs were awarded at a price of $0, indicating they are part of a compensation package.
• Each deferred stock unit represents a contingent right to receive one share of Orthofix common stock.
• The DSUs will vest in full on the first anniversary of their grant date (implied June 18, 2024), contingent on Mr. Bazaar's continued service.
• Vested DSUs will settle and convert into common stock within 45 days of Mr. Bazaar's termination of service with the issuer.
• Following this acquisition, Alan Lee Bazaar's total beneficial ownership of Orthofix common stock stands at 49,824 shares, which includes 24,088 previously reported deferred stock units.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. This is a routine compensation event that aligns director interests with shareholders, which is generally viewed favorably. It does not indicate any significant operational or financial changes, but rather a standard corporate governance practice.

Positives

• The grant of deferred stock units to Director Alan Lee Bazaar aligns his interests with those of the shareholders, as his compensation is tied to the company's future stock performance.
• Equity awards are a standard and effective method of executive and director compensation, promoting long-term commitment and performance.

Future Outlook

The 18,841 deferred stock units granted to Director Alan Lee Bazaar are scheduled to vest on June 18, 2025, contingent upon his continued service to Orthofix Medical Inc. Vested units will convert to common stock upon termination of service.

Industry Context

The granting of deferred stock units to directors is a common practice in the medical device and broader corporate sectors. It serves as a key component of director compensation, designed to align the interests of the board with long-term shareholder value creation.

Comparison to Industry Standards

• The use of deferred stock units as a component of director compensation is a standard practice across publicly traded companies, including those in the medical technology sector.
• This type of equity award is consistent with corporate governance best practices aimed at fostering long-term commitment and aligning director incentives with shareholder returns, similar to compensation structures observed at comparable companies in the healthcare and medical device industries.

Related Party Transactions

• The acquisition of deferred stock units by Director Alan Lee Bazaar constitutes a related party transaction, as it involves an equity award from the company to a member of its board of directors as part of his compensation.

Stakeholder Impact

• Shareholders: The equity award aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The 18,841 deferred stock units are expected to vest on June 18, 2025, subject to Alan Lee Bazaar's continued service.

Key Dates

Keywords

Orthofix Medical Inc., OFIX, SEC Form 4, Director Compensation, Equity Award, Deferred Stock Units, Insider Ownership, Corporate Governance